1. Blair HA. Becotatug Vedotin: First Approval. Drugs. 2026;86(4):573-9.
2. Gao W, Wang Q, Li S, Chen W, Luo B, Xie K, et al. Promising therapeutic efficacy and safety of a novel integrin α6-targeting peptide-drug conjugate in lung adenocarcinoma. Molecular cancer. 2025;24(1):190.
3. Liang Z, Zeng XY, Lv JW, Zhou GQ, Sun Y, Lin L. Advances in the Research of Nasopharyngeal Carcinoma: A Perspective. Cancer innovation. 2026;5(4):e70074.
4. Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. Nature medicine. 2025;31(6):1949-57.
5. Yang Y, Zhou H, Tang L, Qiu S, Han Y, Ji D, et al. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. Lancet (London, England). 2025;406(10516):2235-43.